Since the discovery of the double-helical structure of DNA and postulation of the central dogma of molecular biology, stating that the flow of genetic information goes from DNA to RNA to protein, the ...

Lipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA products (mRNA), most notably used for vaccine production against the recent SARS-CoV-2 pandemic. In this ...

Researchers from IOCB Prague have discovered a new type of substances capable of safely transporting various types of nucleic acids used for therapeutic purposes into cells, from basic building blocks ...

A recent review study discusses fundamental concepts in the successful delivery of nucleic acids in therapeutics. More specifically, this study includes ideas on the design of lipid nanoparticle (LNP) ...

Nucleic acid technology came of age during COVID-19 with biopharma firms developing, testing, mass producing, and shipping mRNA vaccines in record time. However, as the pandemic ebbs, the industry now ...

The two most successful coronavirus vaccines developed in the U.S. – the Pfizer and Moderna vaccines – are both mRNA vaccines. The idea of using genetic material to produce an immune response has ...

Developing and manufacturing innovative LNP delivery technology for respiratory medicine and beyond Expanding Evonik’s CDMO offerings, enabling efficient translation from concept to clinic ...

It’s an exciting time in biopharma, as recent scientific breakthroughs are leading to new therapies with the potential to transform patient care and complex disease management. Cytiva — a global ...

SAN DIEGO, February 03, 2025--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has ...

San Diego CDMO TriLink BioTechnologies is reducing its headcount while its parent company, Maravai LifeSciences, moves forward with a broader restructuring plan. TriLink is letting go of 69 employees ...